| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Amyloid beta-peptide (1-40) rat targets neuronal cells and is involved in the formation of amyloid plaques. It increases ⁴⁵Ca2+ influx and induces neuronal degeneration in the CA1 subregion of rat hippocampus. The peptide accumulates as insoluble extracellular deposits around neurons and causes senile plaques associated with Alzheimer's disease.
|
|---|---|
| ln Vitro |
Beta-amyloid(1-40) (rat) (1 μM; 1 hour) enhances 45Ca2+ inflow and rises Ca2+ in cortical synaptosomes [1]. β-Amyloid(1-40) (rat) (3 nM) promotes neurodegeneration and triggers apoptosis in the CA1 subregion of rat hippocampus neurons [2].
In vitro, Amyloid beta-peptide (1-40) rat increases ⁴⁵Ca2+ influx and induces neuronal degeneration in the CA1 subregion of rat hippocampus. The peptide has both neurotrophic and neurotoxic effects. It is used in neurobiological research to study its role in the formation of amyloid plaques. |
| ln Vivo |
Mice are given 1.7 mg of beta-amyloid(1–40) (rat; ICV for 7 days; Swiss and C57BL/6 mice) to produce learning and memory impairments [3].
In vivo activity data for Amyloid beta-peptide (1-40) rat are not extensively documented. The peptide is used to study amyloid plaque formation and neurodegeneration in animal models. It provides insights into protein aggregation processes underlying neurodegenerative conditions. Further in vivo studies in appropriate models would be needed to characterize its effects. |
| Enzyme Assay |
The in vitro assay for amyloid beta-peptide activity typically involves treating neuronal cells or hippocampal slices with the peptide. Neurotoxicity is assessed by measuring cell viability (MTT, LDH release), calcium influx (using fluorescent calcium indicators), or neuronal degeneration (histological staining). The peptide is dissolved in appropriate buffers and added at various concentrations to cultured cells or tissue slices.
|
| Cell Assay |
For in vitro cell-based assays, primary hippocampal neurons or neuronal cell lines are cultured and treated with Amyloid beta-peptide (1-40) rat at various concentrations. Cell viability is measured using MTT or LDH release assays. Calcium influx is measured using fluorescent calcium indicators such as Fluo-4 or Fura-2. Neuronal degeneration is assessed by morphological analysis or staining. Experiments are typically performed in triplicate.
|
| Animal Protocol |
Animal/Disease Models: Swiss and C57BL/6 mice [3]
Doses: 1.7 mg Route of Administration: intracerebroventricular injection; continued for 7 days Experimental Results: spatial learning and memory impairment. In vivo animal studies for Amyloid beta-peptide (1-40) rat typically involve intracerebroventricular (ICV) injection of the peptide into rodent brains to induce amyloid plaque formation and neurodegeneration. Behavioral testing (such as Morris water maze) may be performed to assess cognitive function. Brain tissue is collected for histological analysis of plaque formation, neuronal loss, and glial activation. Efficacy of potential therapeutic compounds may be tested in this model. |
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Amyloid beta-peptide (1-40) rat are not applicable as it is a research peptide used for inducing pathology rather than as a therapeutic. The peptide has molecular formula C1₉0H2₉1N₅1O₅₇S and molecular weight 4233.76. It is soluble in aqueous buffers and DMSO. Storage at -20degC is recommended.
|
| Toxicity/Toxicokinetics |
Toxicological data for Amyloid beta-peptide (1-40) rat indicate neurotoxic effects at high concentrations. The peptide induces neuronal degeneration in hippocampal neurons. As a research reagent, standard safety precautions should be observed. The compound is for laboratory use only and not intended for human therapeutic applications.
|
| References |
|
| Additional Infomation |
Amyloid beta-peptide (1-40) rat (CAS# 144409-98-3) is a rat form of amyloid beta-peptide found in Alzheimer's disease plaques. It has both neurotrophic and neurotoxic effects and increases calcium influx in neurons. The peptide has molecular formula C1₉0H2₉1N₅1O₅₇S and molecular weight 4233.76. It is used in Alzheimer's disease research and is not for therapeutic use.
|
| Molecular Formula |
C190H291N51O57S
|
|---|---|
| Molecular Weight |
4233.71608281136
|
| Exact Mass |
4233.123
|
| CAS # |
144409-98-3
|
| PubChem CID |
131954565
|
| Appearance |
White to off-white solid powder
|
| LogP |
-12.9
|
| Hydrogen Bond Donor Count |
58
|
| Hydrogen Bond Acceptor Count |
64
|
| Rotatable Bond Count |
143
|
| Heavy Atom Count |
299
|
| Complexity |
10300
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCC(C)C(C(=O)NC(C(C)CC)C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(C(C)C)C(=O)NCC(=O)NCC(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CC(=O)N)NC(=O)C(CO)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C(CCC(=O)N)NC(=O)C(CC3=CNC=N3)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CC4=CC=CC=C4)NC(=O)CNC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(CC5=CNC=N5)NC(=O)CNC(=O)C(CC6=CC=CC=C6)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC(=O)O)N
|
| InChi Key |
KBNPAOMRSZGNFV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C190H291N51O57S/c1-25-101(19)155(184(292)207-87-140(250)213-121(68-93(3)4)172(280)223-120(63-67-299-24)170(278)235-149(95(7)8)182(290)205-82-136(246)201-83-142(252)234-151(97(11)12)187(295)239-154(100(17)18)189(297)298)241-188(296)156(102(20)26-2)240-159(267)103(21)210-137(247)84-202-161(269)113(52-39-41-64-191)219-177(285)129(77-135(195)245)229-181(289)133(90-243)216-141(251)88-206-183(291)150(96(9)10)236-180(288)131(79-148(263)264)230-168(276)118(57-61-144(255)256)218-158(266)105(23)212-171(279)125(72-108-48-35-29-36-49-108)227-174(282)126(73-109-50-37-30-38-51-109)232-186(294)153(99(15)16)238-179(287)122(69-94(5)6)225-164(272)114(53-40-42-65-192)220-166(274)116(55-59-134(194)244)221-176(284)128(75-111-81-199-92-209-111)228-165(273)115(54-43-66-200-190(196)197)224-185(293)152(98(13)14)237-169(277)119(58-62-145(257)258)222-173(281)124(71-107-46-33-28-34-47-107)214-138(248)86-204-163(271)132(89-242)233-178(286)130(78-147(261)262)231-175(283)127(74-110-80-198-91-208-110)215-139(249)85-203-162(270)123(70-106-44-31-27-32-45-106)226-167(275)117(56-60-143(253)254)217-157(265)104(22)211-160(268)112(193)76-146(259)260/h27-38,44-51,80-81,91-105,112-133,149-156,242-243H,25-26,39-43,52-79,82-90,191-193H2,1-24H3,(H2,194,244)(H2,195,245)(H,198,208)(H,199,209)(H,201,246)(H,202,269)(H,203,270)(H,204,271)(H,205,290)(H,206,291)(H,207,292)(H,210,247)(H,211,268)(H,212,279)(H,213,250)(H,214,248)(H,215,249)(H,216,251)(H,217,265)(H,218,266)(H,219,285)(H,220,274)(H,221,284)(H,222,281)(H,223,280)(H,224,293)(H,225,272)(H,226,275)(H,227,282)(H,228,273)(H,229,289)(H,230,276)(H,231,283)(H,232,294)(H,233,286)(H,234,252)(H,235,278)(H,236,288)(H,237,277)(H,238,287)(H,239,295)(H,240,267)(H,241,296)(H,253,254)(H,255,256)(H,257,258)(H,259,260)(H,261,262)(H,263,264)(H,297,298)(H4,196,197,200)
|
| Chemical Name |
5-[[1-[[2-[[1-[[1-[[1-[[2-[[1-[[1-[[1-[[1-[[1-[[5-amino-1-[[6-amino-1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[2-[[1-[[4-amino-1-[[6-amino-1-[[2-[[1-[[1-[[1-[[2-[[1-[[1-[[1-[[2-[[2-[[1-[(1-carboxy-2-methylpropyl)amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-[2-[(2-amino-3-carboxypropanoyl)amino]propanoylamino]-5-oxopentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. (2). This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.2362 mL | 1.1810 mL | 2.3620 mL | |
| 5 mM | 0.0472 mL | 0.2362 mL | 0.4724 mL | |
| 10 mM | 0.0236 mL | 0.1181 mL | 0.2362 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
